India’s Cumulative COVID-19 Vaccination Coverage exceeds 185.90 Cr

New Delhi : India’s COVID-19 vaccination coverage has exceeded 185.90 Cr (1,85,90,68,616) as per provisional reports till 7 am today. This has been achieved through 2,25,28,350 sessions.

COVID-19 vaccination for the age group 12-14 years was started on 16 March, 2022. So far, more than 2.27 Cr (2,27,48,406) adolescents have been administered with the first dose of COVID-19 vaccine. Similarly, the COVID-19 precaution dose administration for age group 18-59 years also started from 10th April 2022 onwards. 27,401 precaution doses have been administered so far.

The break-up of the cumulative figure as per the provisional report till 7 am today include:


Cumulative Vaccine Dose Coverage
HCWs 1st Dose 10404154
2nd Dose 10005982
Precaution Dose 4550378
FLWs 1st Dose 18413999
2nd Dose 17521993
Precaution Dose 7039110
Age Group 12-14 years 1st Dose 22748406
Age Group 15-18 years 1st Dose 57701433
2nd Dose 39772921
Age Group 18-44 years 1st Dose 555097082
2nd Dose 470729023
Precaution Dose 6190
Age Group 45-59 years 1st Dose 202827997
2nd Dose 186387051
Precaution Dose 21211
Over 60 years 1st Dose 126796922
2nd Dose 116098640
Precaution Dose 12946124
Precaution Dose 2,45,63,013
Total 1,85,90,68,616


Following a continuous downward trend, India’s Active Caseload declines to today 10,889 Active cases now constitute 0.03% of the country’s total Positive Cases.

Consequently, India’s recovery rate stands at 98.76%. 946 patients have recovered in the last 24 hours and the cumulative tally of recovered patients (since the beginning of the pandemic) is now at 4,25,04,329.


796 new cases were reported in the last 24 hours.


The last 24 hours saw a total of 4,06,251 COVID-19 tests being conducted. India has so far conducted over 79.45 Cr (79,45,25,202) cumulative tests.

There has been a sustained fall in the weekly Positivity Rate too. Weekly Positivity Rate in the country currently stands at 0.24% and the Daily Positivity rate is also reported to be 0.20%.


Comments are closed.